<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750190</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-060</org_study_id>
    <nct_id>NCT01750190</nct_id>
  </id_info>
  <brief_title>A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether roxadustat is safe and effective in the&#xD;
      treatment of anemia in participants with chronic kidney disease and not on dialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a screening period of up to 6 weeks, a variable treatment period for individual&#xD;
      participants. In order to complete the treatment period simultaneously for all study&#xD;
      participants, the minimum treatment duration may be less than 52 weeks, with a maximum&#xD;
      treatment duration of up to 3 years after the last participant is randomized, and a&#xD;
      post-treatment follow-up period of 4 weeks. Participants who prematurely discontinued from&#xD;
      treatment will be expected to complete the Early Termination (ET) and End of Study (EOS)&#xD;
      visits. Such participants will be considered non-completers, but they will be expected to&#xD;
      participate in long-term follow-up (LTFU) for cardiovascular events (CV) of interest, vital&#xD;
      status, and hospitalizations until overall study closure unless the participant withdrew&#xD;
      consent for this LTFU data collection. Participants were randomized in a 2:1 ratio to receive&#xD;
      either roxadustat or placebo in a double-blind manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2012</start_date>
  <completion_date type="Actual">September 24, 2018</completion_date>
  <primary_completion_date type="Actual">September 24, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 28 to 52</time_frame>
    <description>The change in Hb from baseline to the average level during the evaluation period (defined as Week 28 until Week 52) is reported. Hb values under the influence of a rescue therapy were not censored. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>The number of participants who achieved a Hb response at 2 consecutive visits at least 5 days apart during the first 24 weeks of treatment, without rescue therapy (that is, red blood cell [RBC] transfusion, erythropoiesis-stimulating agent [ESA], or intravenous [IV] iron) are reported. A Hb response is defined, using central laboratory values, as the following:&#xD;
Hb ≥11 g/dL and Hb increase from baseline by ≥1 g/dL in participants with baseline Hb &gt;8 g/dL, or&#xD;
An increase in Hb by ≥2 g/dL in participants with baseline Hb ≤8.0 g/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 28 to 36</time_frame>
    <description>For Ex-US submission only: Hb values under the influence of a rescue therapy were censored by mixed effect model of repeated measures (MMRM) for up to 6 weeks. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) &gt;Upper Limit of Normal (ULN)</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 28 to 52</time_frame>
    <description>Hb values under the influence of a rescue therapy were not censored in the analysis. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy</measure>
    <time_frame>Weeks 28 to 36</time_frame>
    <description>Hb values under the influence of a rescue therapy were censored by Cochran-Mantel-Haenszel Test for up to 6 weeks. Responder was defined as: Hb ≥10.0 g/dL, which was based on central laboratory values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 12 to 28</time_frame>
    <description>Baseline LDL cholesterol was defined as the last LDL cholesterol value prior to the first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data)</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Progression of chronic kidney disease was measured by rate of change in eGFR over time adjusted by baseline eGFR, with censoring for chronic dialysis or kidney transplant, using random slope and intercept model. Least Square Mean of change from baseline at 1 year was derived based on a random slopes and intercepts model using all available eGFR values (1 baseline and all post-treatment values up to end of treatment period + 7 days or start of dialysis) adjusted on treatment, baseline Hb, baseline eGFR, geographical region, cardiovascular events history at Baseline (yes vs. no), time (continuous value), the interaction terms of baseline eGFR by time, baseline Hb by time, and treatment by time as fixed effects, with random effects of intercept and linear slope of time. All assessments collected after the start of stable dialysis or kidney transplant were excluded from the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Participants with any use of blood/RBC transfusion were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (%) of Participants Who Received Rescue Therapy in the First 24 Weeks and in the First 52 Weeks of Treatment</measure>
    <time_frame>Baseline (Day 1, Week 0) up to Week 24 and up to Week 52</time_frame>
    <description>Rescue therapy included any use of RBC transfusion, ESA, or IV iron.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 12 to 28</time_frame>
    <description>The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). A higher score indicates a general improvement of life quality or well-being. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (%) of Participants Who Experienced Exacerbation of Hypertension</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Exacerbation of hypertension was defined as an increase from baseline of ≥20 millimeter of mercury (mmHg) in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥110 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28</measure>
    <time_frame>Baseline, Weeks 20 to 28</time_frame>
    <description>Baseline MAP was defined as the last MAP value prior to the first dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">922</enrollment>
  <condition>CKD Anemia</condition>
  <arm_group>
    <arm_group_label>Roxadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive roxadustat tablets orally 3 times a week (TIW). The initial dose will be according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing &lt;70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 234.9 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive roxadustat-matching placebo tablets orally TIW. The initial dose will be according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 208.1 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Roxadustat</arm_group_label>
    <other_name>FG-4592</other_name>
    <other_name>ASP1517</other_name>
    <other_name>AZD9941</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic kidney disease Stages 3, 4, or 5 and not receiving dialysis&#xD;
&#xD;
          -  Anemia qualified by measurements of hemoglobin values during screening&#xD;
&#xD;
          -  Additional blood work must be in a safe range for study entry&#xD;
&#xD;
          -  Body weight 45 to 160 kilograms (kg)&#xD;
&#xD;
          -  Willingness to use contraception if of child-bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with an erythropoiesis-stimulating agent (ESA) within 12 weeks prior to&#xD;
             study participation&#xD;
&#xD;
          -  More than 1 dose of intravenous iron within 12 weeks prior to study participation&#xD;
&#xD;
          -  Blood transfusion within 8 weeks prior to study participation&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  Severe congestive heart failure, recent heart attack, stroke, seizure, or blood clot&#xD;
&#xD;
          -  Uncontrolled blood pressure within 2 weeks prior to study participation&#xD;
&#xD;
          -  Renal cell carcinoma&#xD;
&#xD;
          -  History of malignancy, including multiple myeloma or other myelodysplastic syndrome&#xD;
&#xD;
          -  Chronic inflammatory disease that could impact red blood cell production&#xD;
&#xD;
          -  Any prior organ transplant or a scheduled organ transplantation&#xD;
&#xD;
          -  Anticipated elective surgery that is expected to lead to significant blood loss or&#xD;
             anticipated elective heart procedure&#xD;
&#xD;
          -  Gastrointestinal bleeding&#xD;
&#xD;
          -  Any prior treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase&#xD;
             inhibitor (HIF-PHI)&#xD;
&#xD;
          -  Recent use of an investigational drug or treatment, or participation in an&#xD;
             investigational study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Eisner, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>FibroGen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Cutler Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Caldwell</city>
        <state>Idaho</state>
        <zip>83605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ciudad Evita</city>
        <state>Buenos Aires</state>
        <zip>B1178IFA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Moron</city>
        <state>Buenos Aires</state>
        <zip>B1708DPN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>González Catán</city>
        <state>Provincia De Buenos Aires</state>
        <zip>B1759LTF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Junin</city>
        <state>Provincia De Buenos Aires</state>
        <zip>B6000GMA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Pergamino</city>
        <state>Provincia De Buenos Aires</state>
        <zip>B2700CPM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Product</name>
      <address>
        <city>Villa Domínico</city>
        <state>Provincia De Buenos Aires</state>
        <zip>B1874GBA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ciudad de Cordoba</city>
        <state>Provincia De Cordoba</state>
        <zip>X5002HWE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1852FZD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425BPJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1429BWN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5002AOQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KET</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Corrientes</city>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Salta</city>
        <zip>A4402BGJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Gosford</city>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hobart</city>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Launceston</city>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>New Lambton Heights</city>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Temuco</city>
        <state>Region De La Araucania</state>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>8431657</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <state>Pokfulam</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chai Wan</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shatin</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tai Po</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Anyang-Si</city>
        <state>Gyeonggi-Do</state>
        <zip>431-796</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Goyang-Si</city>
        <state>Gyeonggi-Do</state>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Guri-Si</city>
        <state>Gyeonggi-Do</state>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seongnam-Si</city>
        <state>Gyeonggi-Do</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>133-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Alor Setar</city>
        <zip>05460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kajang</city>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Pulau Pinang</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Sungai Petani</city>
        <zip>080000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Taiping</city>
        <zip>34000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>06100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97133</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20128</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tauranga</city>
        <zip>3143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bellavista</city>
        <state>Callao</state>
        <zip>Callao 2</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>San Martin de Porres</city>
        <state>Lima</state>
        <zip>Lima 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 13</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Dasmarinas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Davao City</city>
        <state>Davao</state>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Pasig</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>768828</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hualien City</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>433</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tainan City</city>
        <zip>433</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <results_first_submitted>September 1, 2021</results_first_submitted>
  <results_first_submitted_qc>September 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2021</results_first_posted>
  <disposition_first_submitted>October 23, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>November 12, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 18, 2019</disposition_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>chronic kidney disease (CKD)</keyword>
  <keyword>non-dialysis</keyword>
  <keyword>Hemoglobin (Hb)</keyword>
  <keyword>End-Stage Renal Disease</keyword>
  <keyword>erythropoeitin</keyword>
  <keyword>ASP1517</keyword>
  <keyword>erythropoeisis stimulating-agent</keyword>
  <keyword>AZD9941</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT01750190/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT01750190/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets orally 3 times a week (TIW). The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing &lt;70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="616"/>
                <participants group_id="P2" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="611"/>
                <participants group_id="P2" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="608"/>
                <participants group_id="P2" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="349"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy (Including Erythropoiesis-Stimulating Agent Rescue)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study/Site Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Kidney Transplant</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dialysis</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than Specified</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population included all randomized/enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="616"/>
            <count group_id="B2" value="306"/>
            <count group_id="B3" value="922"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="417"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="345"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="375"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="551"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="451"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="673"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian/ Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy</title>
        <description>The change in Hb from baseline to the average level during the evaluation period (defined as Week 28 until Week 52) is reported. Hb values under the influence of a rescue therapy were not censored. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 28 to 52</time_frame>
        <population>ITT Population included all randomized/enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy</title>
          <description>The change in Hb from baseline to the average level during the evaluation period (defined as Week 28 until Week 52) is reported. Hb values under the influence of a rescue therapy were not censored. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.</description>
          <population>ITT Population included all randomized/enrolled participants.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="616"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.10" spread="0.75"/>
                    <measurement group_id="O2" value="9.09" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Weeks 28 to 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.952"/>
                    <measurement group_id="O2" value="0.16" spread="0.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the multiple imputation strategy by combining the results of analysis of covariance (ANCOVA) model with baseline Hb and baseline estimated glomerular filtration rate (eGFR) as covariates and treatment and other randomization stratification factors, except baseline Hb (≤8 g/dL versus &gt;8 g/dL) and eGFR (&lt;30 versus ≥30 milliliters [mL]/minutes [min]/1.73 meters [m]^2), as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>MI (Multiple Imputation) ANCOVA</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>1.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.735</ci_lower_limit>
            <ci_upper_limit>1.967</ci_upper_limit>
            <estimate_desc>Roxadustat - Placebo Treatment Difference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy</title>
        <description>The number of participants who achieved a Hb response at 2 consecutive visits at least 5 days apart during the first 24 weeks of treatment, without rescue therapy (that is, red blood cell [RBC] transfusion, erythropoiesis-stimulating agent [ESA], or intravenous [IV] iron) are reported. A Hb response is defined, using central laboratory values, as the following:&#xD;
Hb ≥11 g/dL and Hb increase from baseline by ≥1 g/dL in participants with baseline Hb &gt;8 g/dL, or&#xD;
An increase in Hb by ≥2 g/dL in participants with baseline Hb ≤8.0 g/dL</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>FAS Population included of all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy</title>
          <description>The number of participants who achieved a Hb response at 2 consecutive visits at least 5 days apart during the first 24 weeks of treatment, without rescue therapy (that is, red blood cell [RBC] transfusion, erythropoiesis-stimulating agent [ESA], or intravenous [IV] iron) are reported. A Hb response is defined, using central laboratory values, as the following:&#xD;
Hb ≥11 g/dL and Hb increase from baseline by ≥1 g/dL in participants with baseline Hb &gt;8 g/dL, or&#xD;
An increase in Hb by ≥2 g/dL in participants with baseline Hb ≤8.0 g/dL</description>
          <population>FAS Population included of all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>77.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.73</ci_lower_limit>
            <ci_upper_limit>134.48</ci_upper_limit>
            <estimate_desc>Roxadustat/Placebo Odds ratio</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy</title>
        <description>For Ex-US submission only: Hb values under the influence of a rescue therapy were censored by mixed effect model of repeated measures (MMRM) for up to 6 weeks. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 28 to 36</time_frame>
        <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Number Analyzed' signifies participants evaluable at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy</title>
          <description>For Ex-US submission only: Hb values under the influence of a rescue therapy were censored by mixed effect model of repeated measures (MMRM) for up to 6 weeks. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.</description>
          <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Number Analyzed' signifies participants evaluable at the specified timepoint.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="608"/>
                    <count group_id="O2" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.09" spread="0.749"/>
                    <measurement group_id="O2" value="9.09" spread="0.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Weeks 28 to 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="520"/>
                    <count group_id="O2" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="1.067"/>
                    <measurement group_id="O2" value="0.20" spread="0.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using MMRM with baseline Hb and baseline eGFR as covariates, and treatment, visit, visit-by-treatment interaction, and the randomization stratification factors, except baseline Hb (≤8 g/dL versus &gt;8 g/dL) and eGFR (&lt;30 versus ≥30 mL/min/1.73m^2), as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM Analysis</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>1.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.730</ci_lower_limit>
            <ci_upper_limit>2.037</ci_upper_limit>
            <estimate_desc>Roxadustat - placebo treatment difference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) &gt;Upper Limit of Normal (ULN)</title>
        <description>Hb values under the influence of a rescue therapy were not censored in the analysis. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study treatment.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 28 to 52</time_frame>
        <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) &gt;Upper Limit of Normal (ULN)</title>
          <description>Hb values under the influence of a rescue therapy were not censored in the analysis. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study treatment.</description>
          <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.10" spread="0.750"/>
                    <measurement group_id="O2" value="8.99" spread="0.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Weeks 28 to 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.933"/>
                    <measurement group_id="O2" value="0.18" spread="0.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the multiple imputation strategy by combining the results of ANCOVA model with baseline Hb and baseline eGFR as covariates , and treatment and other randomization stratification factors, except baseline Hb (≤8 g/dL versus &gt;8 g/dL) and eGFR (&lt;30 versus ≥30 mL/min/1.73m^2 ), as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>MI ANCOVA</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>1.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.122</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.663</ci_lower_limit>
            <ci_upper_limit>2.143</ci_upper_limit>
            <estimate_desc>Roxadustat - placebo treatment difference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy</title>
        <description>Hb values under the influence of a rescue therapy were censored by Cochran-Mantel-Haenszel Test for up to 6 weeks. Responder was defined as: Hb ≥10.0 g/dL, which was based on central laboratory values.</description>
        <time_frame>Weeks 28 to 36</time_frame>
        <population>FAS Population consisted of all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy</title>
          <description>Hb values under the influence of a rescue therapy were censored by Cochran-Mantel-Haenszel Test for up to 6 weeks. Responder was defined as: Hb ≥10.0 g/dL, which was based on central laboratory values.</description>
          <population>FAS Population consisted of all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>15.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.79</ci_lower_limit>
            <ci_upper_limit>22.189</ci_upper_limit>
            <estimate_desc>Roxadustat/placebo odds ratio</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28</title>
        <description>Baseline LDL cholesterol was defined as the last LDL cholesterol value prior to the first dose of study drug.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 12 to 28</time_frame>
        <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Number Analyzed' signifies participants evaluable at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28</title>
          <description>Baseline LDL cholesterol was defined as the last LDL cholesterol value prior to the first dose of study drug.</description>
          <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Number Analyzed' signifies participants evaluable at the specified timepoint.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="608"/>
                    <count group_id="O2" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.74" spread="39.09"/>
                    <measurement group_id="O2" value="96.39" spread="40.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Weeks 12 to 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="564"/>
                    <count group_id="O2" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.48" spread="29.60"/>
                    <measurement group_id="O2" value="0.22" spread="29.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using MMRM with baseline LDL cholesterol as a covariate, and treatment, visit, visit-by-treatment interaction, and the randomization stratification factors as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM Analysis</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-17.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.65</ci_lower_limit>
            <ci_upper_limit>-13.87</ci_upper_limit>
            <estimate_desc>Roxadustat- placebo treatment difference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data)</title>
        <description>Progression of chronic kidney disease was measured by rate of change in eGFR over time adjusted by baseline eGFR, with censoring for chronic dialysis or kidney transplant, using random slope and intercept model. Least Square Mean of change from baseline at 1 year was derived based on a random slopes and intercepts model using all available eGFR values (1 baseline and all post-treatment values up to end of treatment period + 7 days or start of dialysis) adjusted on treatment, baseline Hb, baseline eGFR, geographical region, cardiovascular events history at Baseline (yes vs. no), time (continuous value), the interaction terms of baseline eGFR by time, baseline Hb by time, and treatment by time as fixed effects, with random effects of intercept and linear slope of time. All assessments collected after the start of stable dialysis or kidney transplant were excluded from the analysis.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data)</title>
          <description>Progression of chronic kidney disease was measured by rate of change in eGFR over time adjusted by baseline eGFR, with censoring for chronic dialysis or kidney transplant, using random slope and intercept model. Least Square Mean of change from baseline at 1 year was derived based on a random slopes and intercepts model using all available eGFR values (1 baseline and all post-treatment values up to end of treatment period + 7 days or start of dialysis) adjusted on treatment, baseline Hb, baseline eGFR, geographical region, cardiovascular events history at Baseline (yes vs. no), time (continuous value), the interaction terms of baseline eGFR by time, baseline Hb by time, and treatment by time as fixed effects, with random effects of intercept and linear slope of time. All assessments collected after the start of stable dialysis or kidney transplant were excluded from the analysis.</description>
          <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
          <units>ml/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="0.363"/>
                    <measurement group_id="O2" value="-3.10" spread="0.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6924</p_value>
            <method>ANCOVA</method>
            <method_desc>MI ANCOVA</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.528</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.827</ci_lower_limit>
            <ci_upper_limit>1.245</ci_upper_limit>
            <estimate_desc>Roxadustat - placebo treatment difference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment</title>
        <description>Participants with any use of blood/RBC transfusion were reported.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment</title>
          <description>Participants with any use of blood/RBC transfusion were reported.</description>
          <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>From a Cox Proportional hazards model adjusting for baseline Hb, baseline eGFR and other randomization stratification factors, except baseline Hb (≤8 g/dL versus &gt;8 g/dL) and eGFR (&lt;30 versus ≥30 mL/min/1.73 m^2).</p_value_desc>
            <method>Cox Proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.165</ci_lower_limit>
            <ci_upper_limit>0.406</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number (%) of Participants Who Received Rescue Therapy in the First 24 Weeks and in the First 52 Weeks of Treatment</title>
        <description>Rescue therapy included any use of RBC transfusion, ESA, or IV iron.</description>
        <time_frame>Baseline (Day 1, Week 0) up to Week 24 and up to Week 52</time_frame>
        <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number (%) of Participants Who Received Rescue Therapy in the First 24 Weeks and in the First 52 Weeks of Treatment</title>
          <description>Rescue therapy included any use of RBC transfusion, ESA, or IV iron.</description>
          <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>First 24 Weeks of Treatment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>From a Cox Proportional hazards model adjusting for baseline Hb, baseline eGFR and the randomization stratification factors, except baseline Hb (&lt;=8 g/dL versus &gt;8 g/dL) and eGFR (&lt;30 versus &gt;=30 mL/min/1.73m^2).</p_value_desc>
            <method>Cox Proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.267</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>First 52 Weeks of Treatment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>From a Cox Proportional hazards model adjusting for baseline Hb, baseline eGFR and other randomization stratification factors, except baseline Hb (≤8 g/dL versus &gt;8 g/dL) and eGFR (&lt;30 versus ≥30 mL/min/1.73 m^2).</p_value_desc>
            <method>Cox Proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.138</ci_lower_limit>
            <ci_upper_limit>0.276</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28</title>
        <description>The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). A higher score indicates a general improvement of life quality or well-being. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 12 to 28</time_frame>
        <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28</title>
          <description>The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). A higher score indicates a general improvement of life quality or well-being. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.</description>
          <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable at the specified timepoint.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning subscore: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="605"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.16" spread="10.121"/>
                    <measurement group_id="O2" value="41.35" spread="10.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning subscore: Change at Weeks 12 to 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="558"/>
                    <count group_id="O2" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="7.302"/>
                    <measurement group_id="O2" value="-0.27" spread="7.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality subscore: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="604"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.19" spread="10.146"/>
                    <measurement group_id="O2" value="47.62" spread="9.774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality subscore: Change at Weeks 12 to 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="558"/>
                    <count group_id="O2" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="8.705"/>
                    <measurement group_id="O2" value="1.02" spread="8.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number (%) of Participants Who Experienced Exacerbation of Hypertension</title>
        <description>Exacerbation of hypertension was defined as an increase from baseline of ≥20 millimeter of mercury (mmHg) in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥110 mmHg.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number (%) of Participants Who Experienced Exacerbation of Hypertension</title>
          <description>Exacerbation of hypertension was defined as an increase from baseline of ≥20 millimeter of mercury (mmHg) in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥110 mmHg.</description>
          <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28</title>
        <description>Baseline MAP was defined as the last MAP value prior to the first dose of study drug.</description>
        <time_frame>Baseline, Weeks 20 to 28</time_frame>
        <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Number Analyzed' signifies participants evaluable at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28</title>
          <description>Baseline MAP was defined as the last MAP value prior to the first dose of study drug.</description>
          <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Number Analyzed' signifies participants evaluable at the specified timepoint.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="608"/>
                    <count group_id="O2" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.16" spread="8.538"/>
                    <measurement group_id="O2" value="91.53" spread="8.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Weeks 20 to 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="546"/>
                    <count group_id="O2" value="243"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="8.648"/>
                    <measurement group_id="O2" value="-0.12" spread="7.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline (Day 1, Week 0) up to 28 days after the last dose of study drug (maximum treatment duration was 234.9 weeks for roxadustat and 208.1 weeks for placebo). Mortality presented is for the timeframe of Baseline (Day 1, Week 0) up to end of treatment (maximum treatment duration was 234.9 weeks for roxadustat and 208.1 weeks for placebo).</time_frame>
      <desc>The Safety Population included all randomized participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 234.9 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received roxadustat-matching placebo tablets orally TIW. The initial dose was according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing &lt;70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) was performed based upon regular measurement of Hb levels until the participant achieved central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level was reached, the participant entered the maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration was 208.1 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="321" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Choroidal neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Anal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Portal hypertensive gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Medical device site irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Terminal state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gallbladder cholesterolosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hepatic cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cellulitis gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sinobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dialysis disequilibrium syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haemodilution</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vascular access malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Calciphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Chest wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic hyperglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Intracranial mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Post cardiac arrest syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic end stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <description>This is a sex-specific adverse event that only affects male participants.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <description>This is a sex-specific adverse event that only affects female participants.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <description>This is a sex-specific adverse event that only affects male participants.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Obliterative bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pleuroperitoneal communication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Necrobiosis lipoidica diabeticorum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="468" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="216" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hyperphosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="611"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The multisite consortium can publish any time after the data is collected and analyzed by FibroGen.&#xD;
The investigator can only publish after the multisite consortium publishes (or tries to publish and fails).&#xD;
FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Information Desk</name_or_title>
      <organization>FibroGen, Inc.</organization>
      <phone>415-978-1441</phone>
      <email>060study@fibrogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

